Skip to main content

Alpha Agonists

Category: Pharmacology > Voiding & Outlet

Overview​

Alpha-adrenergic agonists raise bladder-neck and urethral smooth-muscle tone. In urology they are used for three purposes: retrograde ejaculation or anejaculation (the best-supported use), selected stress urinary incontinence , and neurogenic orthostatic hypotension in spinal cord injury (midodrine). They are just as important as a cause of functional outlet obstruction and urinary retention, most often from over-the-counter decongestants.[1][2][3]

The ejaculatory and adult stress-incontinence regimens described here are off-label. Midodrine is labeled for symptomatic orthostatic hypotension, pseudoephedrine for nasal congestion, and imipramine for depression and childhood enuresis.[11][12][17]

Mechanism of Action​

The bladder neck, proximal urethra and (in men) prostate, seminal vesicles, vas and ejaculatory ducts carry α1-adrenoceptors. Stimulation contracts this smooth muscle.

  • Direct agonists (midodrine, via its active metabolite desglymidodrine; phenylephrine) bind α1 receptors.
  • Mixed or indirect agents (pseudoephedrine, ephedrine, phenylpropanolamine) release norepinephrine and also act directly.
  • Imipramine is not an agonist. It blocks noradrenaline reuptake, which raises adrenergic tone at the bladder neck and seminal tract. It is grouped with the sympathomimetics for ejaculatory disorders.[3][5]

The same action explains the main harms: closing the bladder neck causes retention in men with BPH or in women with outlet obstruction, and systemic α1 stimulation raises blood pressure.

Agents in This Class​

Generic nameBrand / sourceRouteUrologic role and notes
PseudoephedrineSudafed and generics (OTC)OralRetrograde ejaculation (off-label). Also a common cause of drug-induced retention.
MidodrineGenericsOralLabeled for symptomatic orthostatic hypotension. Off-label for anejaculation in spinal cord injury; trialed in SUI.
EphedrineInjectable (anesthesia); oral products restrictedOral / IVNamed by EAU for retrograde ejaculation. Little modern urologic trial data.
Phenylpropanolamine (PPA)Formerly OTC decongestant and appetite suppressantOralRemoved from the US market from November 2000 (FDA request after an association with hemorrhagic stroke). Most SUI trials in the Cochrane review used it, so that evidence is historical.[1][10][13]
ImipramineTofranil and genericsOralTricyclic used off-label for retrograde ejaculation.

Indications in Reconstructive and Functional Urology​

Retrograde ejaculation and anejaculation​

Retrograde ejaculation means semen enters the bladder during climax, usually because the bladder neck fails to close during emission. Bladder-neck surgery and neurologic lesions can cause it.[18] EAU Neuro-Urology 2026 states that sympathomimetics that contract the bladder neck (imipramine, ephedrine, pseudoephedrine, phenylpropanolamine) may reverse it. If antegrade ejaculate is not achieved, sperm can be recovered from post-ejaculatory urine.[3]

The evidence is uncontrolled and heterogeneous. A systematic review of 88 retrograde-ejaculation studies called for controlled trials.[5]

StudyDesign and regimenResult
Arafa 2008 (diabetic men, n = 33)[6]Sequential courses: imipramine 25 mg twice daily, pseudoephedrine 120 mg twice daily, then bothAmong 23 men with complete retrograde ejaculation, 11 regained antegrade ejaculate with pseudoephedrine and 16 with the combination; the imipramine label advises avoiding sympathomimetic decongestants.[17]
Shoshany 2017 (n = 20)[7]Pseudoephedrine 60 mg every 6 h the day before semen analysis, plus two doses on the dayAntegrade sperm recovered in 7 of 12 complete cases; ≥50% count increase in 5 of 8 partial cases
Conduit 2024, after RPLND (single-arm phase II)[8]Pseudoephedrine 60 mg every 6 h for six dosesPrimary endpoint (>39 million sperm) met in 4 of 22 (18%); efficacy lower than expected

Practical use. A short course is timed to semen collection; post-ejaculatory urine is interpreted alongside the antegrade specimen, and assisted reproduction is planned in parallel.[7] In Shoshany’s mixed-etiology series, antegrade sperm appeared in 7/12 men with complete retrograde ejaculation, while 5/8 with partial retrograde ejaculation had a sperm-count increase of at least 50%[7]; after RPLND, 4/22 met Conduit’s prespecified threshold of >39 million sperm per ejaculate[8]. These populations and endpoints differ.[7][8]

For delayed ejaculation, AUA/SMSNA finds insufficient evidence to assess the risk-benefit ratio of oral pharmacotherapy . Its Table 3 reports pseudoephedrine 60–120 mg 120–150 minutes before sexual activity, ephedrine 15–60 mg one hour before sexual activity and imipramine 25–75 mg daily as regimens with possible efficacy.[18]

Spinal cord injury: anejaculation and sperm retrieval​

Soler’s uncontrolled series reported antegrade or retrograde ejaculation with adjunctive midodrine during penile vibratory stimulation; a later pilot randomized 23 men, of whom 20 completed treatment, and reported antegrade ejaculation in 1/10 midodrine recipients versus 2/10 placebo recipients.[4][19] In a 2008 Soler series, 158 men with spinal cord injury who failed baseline penile vibration received weekly stimulation with escalating midodrine.[20] An earlier Soler report specifies oral midodrine 30–120 minutes before stimulation, increasing by 7.5 mg to a 30 mg maximum.[4] Antegrade or retrograde ejaculation was reported in 102/158 (64.6%); response was more frequent with complete lesions and upper-motor-neuron lesions above T10.[4][20] The mean midodrine dose required for ejaculation in Soler’s responders was 18.7 mg.[4] Mean arterial pressure rose by up to about 10 mm Hg; systolic pressure exceeded 200 mm Hg in some men with tetraplegia, and 16/158 developed intense autonomic dysreflexia requiring oral nicardipine during midodrine-assisted vibrostimulation.[4][20]

EAU Neuro-Urology 2026 describes oral midodrine as a possible adjunct to vibrostimulation. It strongly recommends counseling men with SCI at or above T6 and fertility clinics about potentially life-threatening autonomic dysreflexia.[3] Monitor blood pressure throughout each attempt.

Neurogenic orthostatic hypotension​

In spinal cord injury and other autonomic failure, midodrine is labeled for symptomatic orthostatic hypotension based on improved standing blood pressure, with continued treatment limited to patients who report symptomatic improvement.[11] Consensus guidance pairs treatment with monitoring and management of supine hypertension.[15] In a 19-person SCI crossover trial of 30-day dosing (10 completed both periods), midodrine reduced hypotensive readings but increased blood-pressure variability and autonomic-dysreflexia symptom intensity without improving orthostatic symptoms.[21]

Stress urinary incontinence​

Adrenergic agonists are not a routine option. The Cochrane review (22 randomized trials, 1,099 women, 673 receiving an adrenergic drug; PPA in 11 trials, midodrine in 2) found limited evidence that they beat placebo for pad changes, incontinence episodes and subjective symptoms, and too little evidence to compare them with pelvic floor training or estrogen. Adverse effects were reported by more than a quarter of women, with similar numbers in adrenergic, placebo and alternative-drug groups; recognized adrenergic effects led to treatment cessation in 4%.[1] Arrhythmias and severe hypertension have also been reported.[1] No trial included men.[1] In a placebo-controlled midodrine phase II trial, urethral closure pressure did not change at 4 weeks, although global assessments favored treatment.[9]

EAU 2026 female LUTS guidance describes only "weak evidence" for adrenergic agonists and recommends offering duloxetine (where licensed), not an adrenergic agonist, to selected women with SUI unresponsive to conservative care who wish to avoid invasive treatment .[2] The AUA/SUFU surgical-treatment guideline (2017, amended 2023) gives no recommendation on adrenergic drug therapy.[16] NICE NG123 advises against offering imipramine (along with flavoxate and propantheline) for urinary incontinence or overactive bladder in women.[14]

Dosing and Administration​

Doses are for reference. Confirm against the current label and local protocol.

AgentLabeled doseUrologic (off-label) regimens in the studies above
MidodrineOrthostatic hypotension: 10 mg three times daily, in the daytime only; not after the evening meal or within 4 h of bedtime. Start at 2.5 mg in renal impairment.[11]In Soler’s off-label cohort of men with SCI and anejaculation after failed vibrostimulation, midodrine started at 7.5 mg for tetraplegia or 15 mg for paraplegia, then was escalated weekly to a maximum single 30-mg dose 30–120 min before repeat monitored vibrostimulation; the orthostatic-hypotension label recommends 10 mg per dose and reports severe persistent supine hypertension in about 45% after a single 20-mg dose.[4][11][20]
PseudoephedrineOTC 60 mg every 4–6 h, maximum 4 tablets (240 mg) in 24 h, age 12 and older[12]60 mg every 6 h for a short course around semen collection[7][8]; 120 mg twice daily in diabetic retrograde ejaculation[6]
ImipramineDepression: outpatients start at 75 mg/day and may increase to 150 mg/day; doses over 200 mg/day are not recommended. Childhood enuresis (age 6 and older): 25 mg one hour before bedtime. The label gives no retrograde-ejaculation dose, has a boxed warning for suicidality in children, adolescents and young adults, and contraindicates MAO inhibitors. It calls for extreme caution with cardiovascular disease (cardiac surveillance at all doses), prior urinary retention, narrow-angle glaucoma or seizure disorder.[17]25 mg twice daily in the diabetic series[6]
Ephedrine, PPANo labeled urologic doseEphedrine has been reported for DE, with uncertain risk-benefit (AUA/SMSNA Statement 23 and Table 3). PPA is off the US market.[18][13]

Contraindications and Precautions​

  • Midodrine boxed warning: it can cause marked elevation of supine blood pressure, so it should be used only in patients whose lives are considerably impaired despite standard care. Contraindicated with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma and thyrotoxicosis; do not use in patients with persistent and excessive supine hypertension. Use cautiously in any retention problem, because desglymidodrine acts on bladder-neck alpha receptors. Avoid MAO inhibitors and linezolid. Avoid concurrent pressor drugs such as phenylephrine, pseudoephedrine or ephedrine; if coadministration cannot be avoided, monitor blood pressure closely. Use caution with cardiac glycosides (bradycardia or AV block) and beta-blockers. Animal studies showed embryo resorption and reduced fetal weight (former Pregnancy Category C). Pediatric safety is not established.[11]
  • Pseudoephedrine (OTC label): do not use with a prescription MAOI or within 2 weeks of stopping one. Ask a clinician first with heart disease, hypertension, thyroid disease, diabetes or difficulty urinating from an enlarged prostate. Pregnant or breastfeeding patients should ask a health professional first.[12] The imipramine label advises avoiding sympathomimetic decongestants because tricyclic antidepressants can potentiate catecholamine effects.[17]
  • Functional outlet obstruction: EAU lists decongestant alpha-agonists such as pseudoephedrine as a cause of functional female bladder outlet obstruction and retention.[2] The AUA 2026 BPH guideline likewise lists chronic decongestant use among medications that increase outlet resistance and should be captured in the history of men with predominant voiding LUTS.[26]
  • PPA: the FDA asked manufacturers to stop marketing it in November 2000 after the Hemorrhagic Stroke Project. In a case-control study of adults aged 18–49, PPA-containing appetite-suppressant use within the preceding three days was associated with hemorrhagic stroke in women (adjusted odds ratio 16.6, 95% CI 1.5–182).[10][13]
  • Spinal cord injury: rapid blood-pressure rises and autonomic dysreflexia; monitor during dosing and stimulation.[3][4]

Perioperative Considerations​

  • Ask about OTC decongestants before and after outlet or prolapse surgery in patients with new retention or a weak stream. Stopping the drug may resolve the obstruction.
  • Avoid midodrine with MAO inhibitors or linezolid and pseudoephedrine with prescription MAO inhibitors; if pseudoephedrine is given during linezolid treatment, monitor blood pressure for a pressor response.[11][12][25]
  • Sympathomimetics can compound perioperative hypertension and tachyarrhythmia; review them at pre-anesthesia assessment.

Evidence Summary​

IndicationEvidence levelKey sourceNotes
Retrograde ejaculation / anejaculationUncontrolled retrograde-ejaculation series; one placebo-controlled RCT in non-SCI organic anejaculationKamischke 1999; Arafa 2008; Shoshany 2017; Conduit 2024; Safarinejad 2009[5][6][7][8][22]EAU 2026 lists sympathomimetics as an option
Sperm retrieval in spinal cord injuryLarge uncontrolled series and small randomized pilotSoler 2007[4]; Leduc 2015[19]Soler reported antegrade or retrograde ejaculation; Leduc found 1/10 versus 2/10 antegrade responses among completers; EAU 2026 states oral midodrine can improve sperm retrieval and warns about autonomic dysreflexia[3]
Female SUIWeak (small, older, largely PPA trials)Cochrane 2005[1]No adrenergic recommendation in AUA/SUFU 2023[16]; EAU weakly recommends duloxetine (where licensed) for selected women with SUI unresponsive to conservative treatment who want to avoid invasive treatment[2]
Neurogenic orthostatic hypotensionConsensus guidanceGibbons 2017Label indication for midodrine

Practical Pearls​

  • Ask every man with retention or a weak stream, and every woman with unexplained retention, about decongestants.
  • For men seeking fertility after RPLND who have aspermia or a low-volume ejaculate, obtain post-orgasmic urinalysis to distinguish retrograde flow from failure of emission .[23] For confirmed retrograde ejaculation after RPLND or with diabetes, a short pseudoephedrine course timed to collection may be discussed ; for lymphadenectomy-related failure of emission, EAU 2026 places penile vibratory stimulation first.[23][24] In Conduit's single-arm post-RPLND trial, 4/22 met the >39-million-sperm endpoint; 7/16 without measurable ejaculate at screening produced an antegrade ejaculate after pseudoephedrine treatment, without a significant sperm-count change (P = 0.14).[8] Plan sperm retrieval or assisted reproduction alongside any drug trial.
  • Monitor blood pressure with midodrine in patients with spinal cord injury, and have a plan for autonomic dysreflexia.

See Also​

References​

1. Alhasso A, Glazener CM, Pickard R, et al. "Adrenergic drugs for urinary incontinence in adults." Cochrane Database Syst Rev. 2005;2005(3):CD001842. doi:10.1002/14651858.CD001842.pub2

2. European Association of Urology. Management of Non-neurogenic Female LUTS: Limited Update. March 2026. Sections 4.2.4.b.2–3 (duloxetine, adrenergic agonists) and the functional bladder outlet obstruction section.

3. European Association of Urology. Neuro-Urology Guidelines. 2026. Section 3.6.2, male fertility.

4. Soler JM, Previnaire JG, Plante P, et al. "Midodrine improves ejaculation in spinal cord injured men." J Urol. 2007;178(5):2082-2086. doi:10.1016/j.juro.2007.07.047

5. Kamischke A, Nieschlag E. "Treatment of retrograde ejaculation and anejaculation." Hum Reprod Update. 1999;5(5):448-474. doi:10.1093/humupd/5.5.448

6. Arafa M, El Tabie O. "Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy." J Sex Med. 2008;5(1):194-198. doi:10.1111/j.1743-6109.2007.00456.x

7. Shoshany O, Abhyankar N, Elyaguov J, et al. "Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation." Andrology. 2017;5(4):744-748. doi:10.1111/andr.12361

8. Conduit C, Lewin J, Hong W, et al. "Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer." BJU Int. 2024;134(5):805-817. doi:10.1111/bju.16481

9. Weil EH, Eerdmans PH, Dijkman GA, et al. "Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study." Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(3):145-150. doi:10.1007/BF02001083

10. Kernan WN, Viscoli CM, Brass LM, et al. "Phenylpropanolamine and the risk of hemorrhagic stroke." N Engl J Med. 2000;343(25):1826-1832. doi:10.1056/NEJM200012213432501

11. Midodrine hydrochloride tablets, USP. Prescribing information. DailyMed, National Library of Medicine (Apotex Corp label).

12. Pseudoephedrine hydrochloride 60 mg tablets. Over-the-counter Drug Facts label. DailyMed, National Library of Medicine (Major Pharmaceuticals label).

13. US Food and Drug Administration. "FDA issues public health warning on phenylpropanolamine." November 2000. fda.gov

14. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NG123. Recommendation 1.4.28.

15. Gibbons CH, Schmidt P, Biaggioni I, et al. "The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension." J Neurol. 2017;264(8):1567-1582. doi:10.1007/s00415-016-8375-x

16. American Urological Association / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Surgical Treatment of Female Stress Urinary Incontinence. 2023. The guideline contains no recommendation for adrenergic drug therapy.

17. Imipramine hydrochloride tablets. US prescribing information (openFDA/DailyMed record effective July 2026): boxed warning, indications, dosage and administration, contraindications. DailyMed

18. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 (2020 guideline).

19. Leduc BE, Fournier C, Jacquemin G, et al. "Midodrine in patients with spinal cord injury and anejaculation: A double-blind randomized placebo-controlled pilot study." J Spinal Cord Med. 2015;38(1):57-62. doi:10.1179/2045772314Y.0000000225

20. Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. "Midodrine improves orgasm in spinal cord-injured men: the effects of autonomic stimulation." J Sex Med. 2008;5(12):2935-2941. doi:10.1111/j.1743-6109.2008.00844.x

21. Wecht JM, Weir JP, Katzelnick CG, Dyson-Hudson TA, Bauman WA, Kirshblum SC. "Clinical trial of home blood pressure monitoring following midodrine administration in hypotensive individuals with spinal cord injury." J Spinal Cord Med. 2023;46(4):531-539. doi:10.1080/10790268.2021.1977904

22. Safarinejad MR. "Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study." Int J Impot Res. 2009;21(4):213-220. doi:10.1038/ijir.2009.19

23. American Urological Association; American Society for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; Amended 2024). Statements 34 and 53. Official guideline.

24. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health. 2026. Sections 6.4.3 and 6.6.3. uroweb.org.

25. Mylan Pharmaceuticals Inc. "Linezolid tablets: prescribing information." DailyMed. Effective July 9, 2026. Label.

26. Goueli R, Badlani GH, Welliver C, et al. "Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation." J Urol. 2026;216(2):143-151. doi:10.1097/JU.0000000000005097